| 1. | DANESE, S., Spitalul IRCCS San Raffaele, Milano, Italia, LEVESQUE, B., Gossamer Bio, Inc., San Diego, Statele Unite ale Americii, FEAGAN, B., University of Western Ontario, Canada, JUCOV, A., dr., BHANDARI, B., Delta Research Partners, Bastrop, SUA, Statele Unite ale Americii, PAI, R., Clinica Mayo, Phoenix, AZ, Statele Unite ale Americii, TAYLOR MEADOWS, K., Gossamer Bio, Inc., San Diego, Statele Unite ale Americii, KIRBY, B., Gossamer Bio, Inc., San Diego, Statele Unite ale Americii, BRUEY, J., Gossamer Bio, Inc., San Diego, Statele Unite ale Americii, OLSON, A., Gossamer Bio, Inc., San Diego, Statele Unite ale Americii, OSTERHOUT, R., Gossamer Bio, Inc., San Diego, Statele Unite ale Americii, VAN BIENE, C., Gossamer Bio, Inc., San Diego, Statele Unite ale Americii, FORD, J., Gossamer Bio, Inc., San Diego, Statele Unite ale Americii, ARANDA, R., Gossamer Bio, Inc., San Diego, Statele Unite ale Americii, RAGHUPATHI, K., Gossamer Bio, Inc., San Diego, Statele Unite ale Americii, SANDBORN, W., University of California, San Diego, Statele Unite ale Americii Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1α stabiliser, for treatment of ulcerative colitis. Alimentary Pharmacology and Therapeutics. 2022, nr. 4(55), 411-401. ISSN 0269-2813 ISSNe 1365-2036. |
